
Law and Regulations
Latest News
Latest Videos

Shorts





CME Content
More News

The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.

Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.

US pharmacies may experience increased requests and questions about peptides as FDA finalizes its rule on the emerging products.

This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.

In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.

Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.

AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.

In part 2 of our pre-election series, detailing key health policies for pharmacists at this year’s midterms, a legal expert touches on MFN pricing, ACA subsidies, and more.

In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession.

With the inherent value medications provide in the greater health care system, Jennifer Hammons, PharmD, DrPH, argues that rural pharmacies deserve the proper recognition.

This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.

As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.

Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

Thomas Lew, MD, ABIM, Molly O’Shea, MD, FAAP, and Jesse Goodman, MD, MPH, discuss vaccine policy changes and their impact on measles outbreaks.

Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.

The 4 key organizations regularly focusing on respiratory virus season released updated vaccine recommendations for 2026-2027.

The American Pharmacists Association, Canadian Pharmacists Association, and International Pharmaceutical Federation release plans for pharmacists’ primary care integration.










































